In the PENELOPE-B trial, the efficacy of adjuvant palbociclib was assessed in patients with hormone receptor-positive, HER2-negative breast cancer who exhibited residual disease following neoadjuvant chemotherapy. This evidence concerns the gene NR4A1 and breast cancer.